NCT00538694View on ClinicalTrials.gov

Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 2000

Primary Completion Date

September 30, 2001

Study Completion Date

September 30, 2001

Conditions
Pneumonia, Bacterial
Interventions
DRUG

daptomycin

All Listed Sponsors
lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00538694 - Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia | Biotech Hunter | Biotech Hunter